Physician profile
Joan E Cain
NPI 1043495732
$1,934.12
in general payments reported to CMS, 2019-2025
32 companies · $898 in 2025
The $898 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $295 · 2024: $741 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,934.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $187.90 | 2023-2025 | Venclexta |
| Regeneron Healthcare Solutions, INC. | $169.85 | 2023-2024 | Libtayo |
| Astrazeneca Pharmaceuticals Lp | $159.06 | 2024-2025 | Enhertu, Lynparza, Tagrisso |
| Daiichi Sankyo INC. | $140.27 | 2024-2025 | Enhertu, Injectafer, Datroway |
| Glaxosmithkline, LLC. | $138.39 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Genentech USA, INC. | $113.60 | 2024-2025 | Venclexta, Polivy, Lunsumio |
| Alexion Pharmaceuticals, INC. | $89.83 | 2023-2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $85.07 | 2024-2025 | Keytruda, Keytruda Qlex |
| Pfizer INC. | $67.18 | 2024-2025 | |
| Gilead Sciences, INC. | $66.63 | 2024 | |
| Lilly USA, LLC | $65.41 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Celgene Corporation | $60.65 | 2024-2025 | Reblozyl, Opdivo |
| Karyopharm Therapeutics INC. | $51.23 | 2024-2025 | Xpovio |
| Adaptive Biotechnologies Corporation | $50.75 | 2024-2025 | Clonoseq |
| Incyte Corporation | $46.99 | 2023-2025 | Zynyz, Monjuvi, Jakafi |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $44.74 | 2023-2024 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $42.82 | 2024-2025 | |
| Tersera Therapeutics LLC | $34.61 | 2023 | Xermelo |
| Aveo Pharmaceuticals, INC. | $32.39 | 2025 | |
| Array Biopharma INC | $30.82 | 2024-2025 | Mektovi, Tukysa, Braftovi |
| E.R. Squibb & Sons, L.L.C. | $30.37 | 2023-2025 | Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $25.38 | 2024 | Alunbrig |
| Cycle Pharmaceuticals INC | $24.64 | 2025 | Phyrago |
| Coherus Oncology, INC. | $23.31 | 2024 | |
| Sobi, INC | $23.17 | 2025 | |
| Janssen Pharmaceuticals, INC | $22.72 | 2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $21.96 | 2025 | |
| Servier Pharmaceuticals LLC | $19.31 | 2024 | |
| Deciphera Pharmaceuticals INC. | $18.83 | 2024 | Qinlock |
| Pharmaessentia USA Corporation | $16.58 | 2025 | Besremi |
| Taiho Oncology, INC. | $15.32 | 2024 | |
| Novocure INC. | $14.34 | 2025 | Optune Lua (Novottf-200t) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joan Cain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.